As the FDA convenes an advisory committee meeting to discuss recent studies showing that many pulse oximeters are less effective when used on patients with darker skin, BioIntelliSense is getting a head start on addressing the issue.

Following Eisai’s successful phase 3 readout of its Alzheimer’s disease treatment lecanemab, the pressure—and optimism—is mounting for top competitor Eli Lilly.

Unity Biotechnology seems to have gotten its crew together behind a common goal in ophthalmology, with the biotech announcing today that its treatment for diabetic macular edema improved vision in a mid-stage trial.

Generations of studying the root cause of schizophrenia have largely converged around a single theory: the “dopamine hypothesis,” which postulates that a combination of genetic susceptibility, substance abuse and environmental stress lead to too much dopamine signaling in the brain. Yet it has remained unclear exactly how excess dopamine leads to psychosis and other schizophrenia symptoms.

Pfizer has halted a pivotal trial of its respiratory syncytial virus (RSV) vaccine candidate early for efficacy, positioning the Big Pharma to file for approval by the end of the year. But with the study only meeting one of its two primary endpoints, the top-line result leaves scope to question how Pfizer will fare against AstraZeneca and Sanofi’s rival antibody.

Abiomed has received FDA approval for a new model of its minimally invasive cardiac pump targeting the right side of the heart, allowing for a new approach the company says will make it easier for patients to walk while implanted with the device.

As wearable health devices like Fitbits and Apple Watches become more advanced, features like daily activity monitoring, heart rate measurements and built-in ECGs can make them crucial tools for managing heart health.

The health data company Evidation is launching a monitoring program to track potential cases of influenza, as the U.S. and northern hemisphere prepares for a particularly early and aggressive flu season.

A FDA advisory committee has blown a hole in Y-mAbs Therapeutics’ hopes of winning approval for its rare disease drug, delivering a damning 0-16 verdict on the question of whether the company showed its candidate improves overall survival.

Two years ago, Santhera refocused its energies on Duchenne muscular dystrophy prospect vamorolone and lung disease candidate lonodelestat. Now, the biotech has decided its lonodelestat dreams may have to die so vamorolone can fly.